A new study has shed light on why immunotherapy does not always work in certain types of cancer. Led by researchers at EMBL's European Bioinformatics Institute (EMBL-EBI) , Cold Spring Harbor Laboratory (CSHL), and the Massachusetts Institute of Technology (MIT), the work focuses on understanding why some tumours fail to respond to immune checkpoint blockade (ICB) therapy, an approved immunotherapy that harnesses the power of the patient's immune system to target and destroy cancer cells. ICB has transformed the treatment landscape for cancer patients.

https://www.miragenews.com/revealing-why-some-patients-dont-respond-to-1084599/

#miragenews